Zobrazeno 1 - 10
of 28
pro vyhledávání: ''
Autor:
Junaid Arshad, Jonathan C. Trent, Priscila Barreto-Coelho, Philippos Apolinario Costa, Brianna Nicole Valdes
Publikováno v:
Cancers, Vol 13, Iss 3525, p 3525 (2021)
Cancers
Cancers
Simple Summary Gastrointestinal stromal tumors (GIST) are the most common type of gastrointestinal sarcomas. Recent treatment advancements have led to a significant improvement in the survival of patients living with GIST. Nevertheless, patients with
Autor:
Klaus Brasso, Jan Stenvang, Diego Iglesias-Gato, Diego S Lima, Luciano D O Souza, Martin Andreas Røder, José M.A. Moreira, Thiago S. Lima
Publikováno v:
Cancers, Vol 13, Iss 1290, p 1290 (2021)
Lima, T S, Iglesias-Gato, D, Souza, L D O, Stenvang, J, Lima, D S, Roder, M A, Brasso, K & Moreira, J M A 2021, ' Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance ', Cancers, vol. 13 . https://doi.org/10.3390/cancers13061290
Cancers
Volume 13
Issue 6
Lima, T S, Iglesias-Gato, D, Souza, L D O, Stenvang, J, Lima, D S, Roder, M A, Brasso, K & Moreira, J M A 2021, ' Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance ', Cancers, vol. 13 . https://doi.org/10.3390/cancers13061290
Cancers
Volume 13
Issue 6
Simple Summary Therapeutic options for the treatment of men with metastatic castration-resistant prostate cancer are limited. Docetaxel—a taxane-based chemotherapeutic agent—was the first treatment to demonstrate significant efficacy in the treat
Autor:
Guiyang Jiang, Takuro Goto, Taichi Mizushima, Eiji Kashiwagi, George J. Netto, Yujiro Nagata, Hiroshi Miyamoto, Yuki Teramoto, Hiroki Ide, Satoshi Inoue, Alexander S. Baras, Zhiming Yang
Publikováno v:
Cancers, Vol 13, Iss 975, p 975 (2021)
Cancers
Volume 13
Issue 5
Cancers
Volume 13
Issue 5
Simple Summary It remains unclear why chemotherapy is often ineffective in patients with bladder cancer. Meanwhile, we previously reported that male sex hormones (i.e., androgens) could considerably reduce the efficacy of cisplatin, an anti-cancer dr
Autor:
Anastassia Löser, Christoph Oing, Carsten Bokemeyer, Hartwig Huland, Wael Y. Mansour, Su Jung Oh-Hohenhorst, Stefanie Meien, Cordula Petersen, Susanne Burdak-Rothkamm, Derya Tilki, Sally Mutiara, Sabrina Köcher, Kai Rothkamm, Alexandra Zielinski, Mohamed E Elsesy, Rudolf Schwarz
Publikováno v:
Cancers, Vol 12, Iss 2467, p 2467 (2020)
CANCERS
Cancers
Volume 12
Issue 9
CANCERS
Cancers
Volume 12
Issue 9
(1) Background: The combination of the first-generation antiandrogens and radiotherapy (RT) has been studied extensively in the clinical setting of prostate cancer (PCa). Here, we evaluated the potential radiosensitizing effect of the second-generati
Autor:
Eric Delabesse, Emilie Bérard, Noémie Gadaud, Isabelle Luquet, Nicolas Lechevalier, Anne-Charlotte de Grande, Audrey Sarry, François Vergez, Laetitia Largeaud, Jean Baptiste Rieu, Harmony Leroy, Arnaud Pigneux, Christian Recher, Emilie Klein, Jean-Philippe Vial, Thibaut Leguay, Audrey Bidet, Pierre-Yves Dumas, Sarah Bertoli
Publikováno v:
Cancers, Vol 12, Iss 2044, p 2044 (2020)
Cancers
Volume 12
Issue 8
Cancers
Volume 12
Issue 8
Two recent phase 3 trials showed that outcomes for relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) patients may be improved by a single-agent tyrosine kinase inhibitor (TKI) (i.e., quizartinib or gilteritinib). In the current stud
Autor:
Kumikov Kagawa, Ariunzaya Bat-Erdene, Hirofumi Tenshin, Shingen Nakamura, Masahiro Abe, Ryohei Sumitani, So Shimizu, Kimiko Sogabe, Mamiko Takahashi, Kengo Udaka, Eiji Tanaka, Jumpei Teramachi, Masahiro Hiasa, Itsuro Endo, Asuka Oda, Toshio Matsumoto, Hirokazu Miki, Shiro Fujii, Masahiro Oura, Mohannad Ashtar, Takeshi Harada, Kotaro Tanimoto, Yoshiki Higa
Publikováno v:
Cancers, Vol 12, Iss 929, p 929 (2020)
Cancers
Volume 12
Issue 4
Cancers
Volume 12
Issue 4
Receptor activator of NF-&kappa
B ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been dem
B ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been dem
Autor:
Masatoshi Kudo
Publikováno v:
Cancers, Vol 12, Iss 1089, p 1089 (2020)
Cancers
Cancers
A successful phase III trial for the combination of atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is groundbreaking because nivolumab and pembrolizumab, both programmed cell
Autor:
Marie Jennifer Reolo, Wee Siong Chew, Gautam Sethi, Jing Kai Chang, Wei Wang, Siti Nasuha Binte Abdul Karim, Muthu K. Shanmugam, Yee Xin Peh, Ping Xiang, Muhammad Zulfaqar Ali, Takaomi Sanda, Deron R. Herr, Andrew Y.Y. Tan, Vineet Kumar, Ting Yu Amelia Yam
Publikováno v:
Cancers, Vol 12, Iss 1, p 211 (2020)
Cancers
Volume 12
Issue 1
Cancers
Volume 12
Issue 1
Ototoxicity is a major adverse effect of platinum-based chemotherapeutics and currently, there remains a lack of United States Food and Drug Administration-approved therapies to prevent or treat this problem. In our study, we examined the role of the
Autor:
Shigeki Ito
Publikováno v:
Cancers, Vol 12, Iss 2, p 265 (2020)
Cancers
Cancers
Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment over the past decade. Many PIs are being developed and evaluated in the preclinical and clinical setting. The first-in-class PI, bortezomib, was approved by the
Autor:
Robert Berahovich, Kai Ding, Hua Zhou, Lijun Wu, Randal May, Dongfeng Qu, Vita M. Golubovskaya, Courtney W. Houchen, Sripathi M. Sureban, Edwin Bannerman-Menson, Shirley Xu
Publikováno v:
Cancers, Vol 12, Iss 1, p 54 (2019)
Cancers
Volume 12
Issue 1
Cancers
Volume 12
Issue 1
CAR-T (chimeric antigen receptor T cells) immunotherapy is effective in many hematological cancers
however, efficacy in solid tumors is disappointing. Doublecortin-like kinase 1 (DCLK1) labels tumor stem cells (TSCs) in genetic mouse models of c
however, efficacy in solid tumors is disappointing. Doublecortin-like kinase 1 (DCLK1) labels tumor stem cells (TSCs) in genetic mouse models of c